

Type 2 Diabetes in adults (medicines update) Committee meeting 13

Date: 20/06/2025

Location: Virtual

Minutes: Final

Committee members present:	
Waqar Shah (Chair)	Present for notes 1 – 10
Chirag Bakhai	Present for notes 1 – 10
Neel Basudev	Present from notes 1 to partway through item 6
Catherine Bewsey	Present for notes 1 – 10
Mimi Chen	Present for notes 1 – 10
Hussain Contractor	Present for notes 1 – 10
Dan Cuthbertson	Present from partway through item 5 to item 10
Anne Dornhorst	Present for notes 1 – 10
Natasha Jacques	Present for notes 1 – 10
Sallianne Kavanagh	Present for notes 1 – 10
Sharon McCarthy	Present for notes 1 – 10
Soon Song	Present from notes 1 to partway through item 7
Annette Swinkels	Present for notes 1 – 10
Dominic Taylor	Present for notes 1 – 10
John Turner	Present for notes 1 – 10
Gosia Wamil	Present for notes 1 – 10

In attendance:		
Astrid Aregui	Senior Guidance Content Designer	Present for notes 1 – 6
Sarah Dwyer	Technical Analyst	Present for notes 1 – 6
James Hawkins	Health Economics Adviser	Present for notes 1 – 6
Lina Manounah	Technical Analyst	Present for notes 1 – 6
Sarah Matthews	Technical Analyst	Present for notes 1 – 6
Caroline Mulvihill	Topic Lead	Present for notes 1 – 6
Adam O’Keefe	Project Manager	Present for notes 1 – 6
Muksitur Rahman	Health Economist	Present for notes 1 – 6
Gary Shield	Resource Impact Manager	Present for notes 1 – 6

Magdalena Watras	Pharmacist Clinical Adviser	Present for notes 1 – 6
George Wood	Senior Technical Analyst	Present for notes 1 – 6

NICE observers:		
Sarah Bromley	Content Designer	Present for notes 1 – 6
Charlotte Fairclough	Technical Analyst	Present for notes 1 – 6

Apologies:	
Sithembile Thokozile Chinaire	Committee member
Hugh Gallagher	Committee member
Sarah Glover	Information Specialist, NICE
Philip Williams	Finance Analyst, NICE

1. Welcome, introductions and apologies				
The Chair welcomed the Committee members and attendees to the thirteenth meeting on Type 2 Diabetes in adults (medicines update). The Chair informed the Committee that apologies had been received. These are noted above.				
2. Confirmation of matter under discussion, and declarations of interest				
The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was initial and subsequent treatment of type 2 diabetes.				
The Chair asked committee members to verbally declare any new interests, these are noted below:				
Name	Role	Declarations of Interest, date declared	Type of interest	Decision taken
Mimi Chen	Committee member, Consultant Diabetologist	Invited to talk at a UK Kidney conference	Direct Non-financial, professional and personal	Declare and participate Not specific to the scope of the guideline update
Anne Dornhorst	Committee member, Consultant Diabetologist	Accepted an invitation from Sanofi to attend European Association of the Study of Diabetes (EASD) conference in Vienna in September 2025,	Direct, financial	Declare and participate Not specific to

		related to PSK lipid drug		the scope of the guideline update
Sallianne Kavanagh	Committee member, Pharmacist	IJDP article accepted about language use in Diabetes	Direct, non-financial professional and personal	Declare and participate Not specific to the scope of the guideline update
Soon Song	Committee member, Consultant Diabetologist	Appointed to NICE Technological Appraisal Committee as expert member	Direct, non-financial professional and personal	Declare and participate Not specific to the scope of the guideline update
Soon Song	Committee member, Consultant Diabetologist	Will be presenting abstract at the European Association of the Study of Diabetes (EASD) conference in Vienna on September 2025 entitled "C-peptide as an adjunctive diagnostic tool for early identification of young-onset type 2 diabetes". Not receiving any financial support to attend this conference.	Direct, non-financial professional and personal	Declare and participate Not specific to the scope of the guideline update
Soon Song	Committee member, Consultant Diabetologist	Publication in BMC Nephrology entitled 'Navigating the complexities of end-stage kidney disease (ESKD) from risk factors to outcome: insights from the UK Biobank cohort'. (BMC Nephrol 26, 168 (2025). https://doi.org/10.1186/s12882-025-04090-7)	Direct, non-financial professional and personal	Declare and participate Not specific to the scope of the guideline update
Gosia Wamil	Committee member, Consultant Cardiologist	Delivered talk on use of GLP1 receptor agonists for heart failure preserved ejection fraction at Royal Society of Medicine	Direct, non-financial professional and personal	Declare and participate Not specific to the scope of the guideline update

The Chair and a senior member of the Developer's team noted that otherwise, the interests declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of previous meeting

The minutes of the previous meeting were accepted as a true and accurate record.

4. Scope of the meeting

The Chair introduced Caroline Mulvihill, Topic Lead, who reminded the group of the reason for this additional meeting and the purpose of the day.

5. Presentation of new HE results

-modified vs standard release metformin

The Chair introduced James Hawkins, Health Economics Adviser and Muksitur Rahman, Health Economist who presented to the committee updated outputs of the health economic model developed in support of the guideline, including for modified vs standard release metformin, given a recent change in pricing.

6. Resource Impact Assessment discussion

The Chair welcomed Gary Shield, Resource Impact Manager who explained the role of NICE's Impact Assessment team in relation to the committee's work.

7. Discussion of implications of new results

The committee discussed the implications of the new results from the health economic model that had been presented to it.

8. Revisit draft recommendations in light of new results

The committee revisited those recommendations impacted by the new results and updated these as appropriate.

9. Insulins discussion

Caroline Mulvihill discussed with the committee plans to update recommendations for insulins.

10. AOB

Adam O'Keefe, Project Manager then outlined next steps to consultation before the Chair thanked participants and closed the meeting.